Serine protease inhibitor Kazal type 1 (SPINK1) as a prognostic marker in stage IV colon cancer patients receiving cetuximab based targeted therapy.

Chen, Yi-Ting; Tsao, Shu-Chuan; Tsai, Hung-Pei; Wang, Jaw-Yuan; Chai, Chee-Yin

Chen, Yi-Ting; Tsao, Shu-Chuan; Tsai, Hung-Pei; Wang, Jaw-Yuan; Chai, Chee-Yin.

Affiliation

Chen YT; Department of Pathology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Tsao SC; Department of Pathology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Tsai HP; Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Wang JY; Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan Department of Surgery, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung, Taiwan Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan Divi
Chai CY; Department of Pathology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan Department of Pathology, Faculty of Medicine, College of Medicine, Kaohsiung Medical Un

J Clin Pathol ; 2016 Apr 22.

Article in En | MEDLINE | ID: mdl-27107100

Key words

CARCINOMA; COLORECTAL CANCER; ONCOLOGY; RECTAL CANCER

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: J Clin Pathol Year: 2016 Document type: Article Affiliation country: Taiwan Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google